Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene FGFR2
Variant V564I
Impact List missense
Protein Effect gain of function
Gene Variant Descriptions FGFR2 V564I lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). V564I confers a gain of function to the Fgfr2 protein as indicated by increased Fgfr2 kinase activity (PMID: 25169980), results in FGF2-independent phosphorylation of Akt and Erk in cell culture (PMID: 29540482), and has been shown to be associated with secondary resistance to FGFR inhibitors (PMID: 25169980).
Associated Drug Resistance Y
Category Variants Paths

FGFR2 mutant FGFR2 act mut FGFR2 V564I

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_000141.5
gDNA chr10:g.121496705C>T
cDNA c.1690G>A
Protein p.V564I
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_000141 chr10:g.121496705C>T c.1690G>A p.V564I RefSeq GRCh38/hg38
NM_000141.4 chr10:g.121496705C>T c.1690G>A p.V564I RefSeq GRCh38/hg38
XM_024447887.2 chr10:g.121488077C>T c.1690G>A p.V564I RefSeq GRCh38/hg38
NM_000141.5 chr10:g.121496705C>T c.1690G>A p.V564I RefSeq GRCh38/hg38
XM_024447887.1 chr10:g.121488077C>T c.1690G>A p.V564I RefSeq GRCh38/hg38
NM_001144916.1 chr10:g.121487376C>T c.1690G>A p.V564I RefSeq GRCh38/hg38
NM_001144916.2 chr10:g.121487376C>T c.1690G>A p.V564I RefSeq GRCh38/hg38
NM_001144916 chr10:g.121487376C>T c.1690G>A p.V564I RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 V564I Advanced Solid Tumor predicted - sensitive Infigratinib Preclinical - Biochemical Actionable In a preclinical study, Truseltiq (infigratinib) failed to inhibit Fgfr2 phosphorylation in cultured cells expressing FGFR2 V564I (PMID: 37270847). 37270847
FGFR2 V564I Advanced Solid Tumor resistant Zoligratinib Preclinical - Cell culture Actionable In a preclinical study, Debio 1347 did not inhibit Fgfr2 phosphorylation in transformed cells over expressing FGFR2 V564I in culture (PMID: 25169980). 25169980
FGFR2 V564I Advanced Solid Tumor predicted - sensitive Pemigatinib Preclinical - Biochemical Actionable In a preclinical study, Pemazyre (pemigatinib) treatment inhibited activity of FGFR2 V564I in a kinase assay (PMID: 36698015). 36698015